RKDA

Arcadia Biosciences, Inc.

4 filings tracked

consumer discretionarybeveragesMICRO (<$300M)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bullishMay 14

Raised $2.1 million through a strategic inducement offer to extend liquidity.

capital raise

60%

bearishMay 14

Net loss of $4.4 million and a formal going concern warning.

earnings miss

90%

bullishMay 14

SG&A expenses reduced by 32% and potential tariff relief on Thai imports.

margin expansion

50%

bearishMay 14

Significant shareholder dilution resulting from inducement offers and new options.

dilution risk

80%

bullishMay 14

Raised $2.1 million through a strategic inducement offer to extend liquidity.

capital raise

60%

bearishMay 14

Net loss of $4.4 million and a formal going concern warning.

earnings miss

90%

bullishMay 14

SG&A expenses reduced by 32% and potential tariff relief on Thai imports.

margin expansion

50%

bearishMay 14

Significant shareholder dilution resulting from inducement offers and new options.

dilution risk

80%

bullishMay 14

Raised $2.1 million through a strategic inducement offer to extend liquidity.

capital raise

60%

bearishMay 14

Net loss of $4.4 million and a formal going concern warning.

earnings miss

90%

bullishMay 14

SG&A expenses reduced by 32% and potential tariff relief on Thai imports.

margin expansion

50%

bearishMay 14

Significant shareholder dilution resulting from inducement offers and new options.

dilution risk

80%

bullishMar 26

SG&A expenses decreased 27% as the company shifted to a lean operating model.

margin expansion

40%

bullishMar 26

Raised $2.1 million in January 2026 through preferred investment option exercises.

capital raise

30%

bearishMar 26

Heavy reliance on equity issuance and option exercises to fund ongoing operations.

dilution risk

70%

bearishMar 26

Potential Nasdaq delisting due to market value of listed securities falling below $5 million.

regulatory action

80%

Filing History

10-QMay 14, 2026

The Q1 2026 filing depicts a company in a race against time, attempting to engineer a turnaround through aggressive cost-cutting and capital infusions while battling systemic insolvency risks. The tension lies between the successful execution of a liquidity-saving inducement offer and the grim reality of a 'going concern' qualification. While the removal of IEEPA tariffs provides a genuine tailwind for margins, the default on the Above Food note underscores the fragility of the company's previous monetization strategies. Ultimately, the impact of this filing is a shift in the investment lens from a growth or merger story to a survival play. The company has successfully stripped away non-core assets and legacy distractions, but it remains highly vulnerable to any further revenue declines or failure to secure additional funding. The next few months will be decisive as the company tests whether Zola's seasonal strength can offset a depleted treasury and a diluted equity base.

10-KMar 26, 2026

The 10-K reveals a company at a crossroads, having successfully shed its identity as a biotech firm but failing to establish a sustainable financial floor as a beverage brand. While the growth in Zola sales and the reduction in operating expenses are positive indicators of a leaner business model, they are overshadowed by a balance sheet characterized by an accumulated deficit of $281.2 million and a critical lack of cash. The write-off of a $4.7 million promissory note from Above Food further highlights the company's struggle to convert strategic divestitures into actual liquidity. Ultimately, the investment case for Arcadia has shifted from a bet on agricultural innovation to a high-stakes gamble on survival and scale. The company's ability to navigate the immediate threat of Nasdaq delisting and manage its razor-thin cash reserves will determine if the Zola brand can reach a critical mass of profitability before the company exhausts its remaining resources. Investors are left weighing a promising product trajectory against a backdrop of severe insolvency risk.